Page last updated: 2024-11-08

1,4-dideoxy-1,4-imino-d-arabinitol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID451991
CHEMBL ID80254
CHEMBL ID305131
SCHEMBL ID143519
MeSH IDM0509154

Synonyms (35)

Synonym
imino-d-arabinitol
CHEMBL80254 ,
MLS002153179
smr001230671
(2r,3r,4r)-2-hydroxymethyl-pyrrolidine-3,4-diol
1,4-dideoxy-1,4-imino-d-arabinito
LOPAC0_000366
259140-24-4
3,4-pyrrolidinediol, 2-(hydroxymethyl-14c)-, (2r,3r,4r)-
(2r,3r,4r)-2-(hydroxymethyl)pyrrolidine-3,4-diol
1,4-dideoxy-1,4-imino-d-arabinitol
1ab ,
NCGC00162133-01
NCGC00162133-02
AKOS006343749
bdbm50016703
chembl305131
bdbm50031485
CCG-204461
HMS2233K17
SCHEMBL143519
(2r,3r,4r)- 2-hydroxymethyl-pyrrolidine-3,4-diol
OQEBIHBLFRADNM-UOWFLXDJSA-N
(2r,3r,4r)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
W-200639
(2r,3r,4r)-2-(hydroxymethyl)-3,4-pyrrolidinediol
DTXSID10180589
1,4-dideoxy-1,4-imino-arabinitol
SDCCGSBI-0050354.P002
NCGC00162133-03
Q27451846
187339-50-0
rel-(2r,3r,4r)-2-(hydroxymethyl)pyrrolidine-3,4-diol
1,4-ideoxy-1,4-mino--rabinitol
3,4-pyrrolidinediol, 2-(hydroxymethyl)-, (2r,3r,4r)-

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"13% for monkeys) with a low oral bioavailability (1."( Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
Honda, T; Izumi, T; Kakuta, M; Kaneno-Urasaki, Y; Koga, T; Murai, T; Namba, E; Nasu, H; Okuno, A, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (31)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
importin subunit beta-1 isoform 1Homo sapiens (human)Potency0.56235.804836.130665.1308AID540253
snurportin-1Homo sapiens (human)Potency0.56235.804836.130665.1308AID540253
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency0.56235.804816.996225.9290AID540253
gemininHomo sapiens (human)Potency1.25890.004611.374133.4983AID624297
TAR DNA-binding protein 43Homo sapiens (human)Potency35.48131.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Trehalase Sus scrofa (pig)IC50 (µMol)2.50002.50002.50002.5000AID338569
Maltase-glucoamylase, intestinalHomo sapiens (human)IC50 (µMol)55.50000.04003.46529.0000AID104667; AID1884462
Glycogen phosphorylase, muscle formOryctolagus cuniculus (rabbit)Ki0.40000.02504.89039.0000AID1276735
Protein kinase C alpha typeRattus norvegicus (Norway rat)IC50 (µMol)290.00000.00000.21931.0000AID338554
Glycogen phosphorylase, liver formHomo sapiens (human)Ki0.40000.40002.75005.1000AID101850
Alpha-glucosidase MAL62Saccharomyces cerevisiae (brewer's yeast)IC50 (µMol)0.84000.84001.42002.0000AID338567
Glucoamylase, intracellular sporulation-specificSaccharomyces cerevisiae S288CIC50 (µMol)0.15000.15000.15000.1500AID296103
Protein kinase C delta typeRattus norvegicus (Norway rat)IC50 (µMol)290.00000.00000.25851.0000AID338554
Protein kinase C epsilon typeRattus norvegicus (Norway rat)IC50 (µMol)290.00000.00000.25851.0000AID338554
Protein kinase C zeta typeRattus norvegicus (Norway rat)IC50 (µMol)290.00000.00000.25851.0000AID338554
Glycogen phosphorylase, liver formRattus norvegicus (Norway rat)IC50 (µMol)1.05000.68000.92671.1000AID1214564; AID1214565
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)8.40000.00031.38338.4000AID342975
Alpha-mannosidase 2C1Rattus norvegicus (Norway rat)IC50 (µMol)100.00001.75001.75001.7500AID108106
Sucrase-isomaltase, intestinalRattus norvegicus (Norway rat)IC50 (µMol)15.50000.04001.848310.0000AID1879700; AID1884460; AID208985; AID324678; AID324679; AID324680; AID338548; AID338550; AID91639
Glycogen debranching enzymeHomo sapiens (human)IC50 (µMol)8.40008.40009.514310.0000AID324673; AID342975
Protein kinase C gamma typeRattus norvegicus (Norway rat)IC50 (µMol)290.00000.00000.26401.1000AID338554
Protein kinase C beta typeRattus norvegicus (Norway rat)IC50 (µMol)290.00000.00000.21641.1000AID338554
Lactase-phlorizin hydrolase Rattus norvegicus (Norway rat)IC50 (µMol)260.00000.12002.98674.4000AID99232
Protein kinase C eta typeRattus norvegicus (Norway rat)IC50 (µMol)290.00000.00000.25851.0000AID338554
Lysosomal alpha-glucosidaseRattus norvegicus (Norway rat)IC50 (µMol)41.66670.08002.50619.8500AID1879698; AID1884458; AID338542
Non-lysosomal glucosylceramidaseHomo sapiens (human)IC50 (µMol)120.00000.00030.08970.3000AID324686
Protein kinase C theta typeRattus norvegicus (Norway rat)IC50 (µMol)290.00000.00000.25851.0000AID338554
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (42)

Processvia Protein(s)Taxonomy
maltose catabolic processMaltase-glucoamylase, intestinalHomo sapiens (human)
starch catabolic processMaltase-glucoamylase, intestinalHomo sapiens (human)
dextrin catabolic processMaltase-glucoamylase, intestinalHomo sapiens (human)
glycogen metabolic processGlycogen phosphorylase, liver formHomo sapiens (human)
5-phosphoribose 1-diphosphate biosynthetic processGlycogen phosphorylase, liver formHomo sapiens (human)
response to bacteriumGlycogen phosphorylase, liver formHomo sapiens (human)
glucose homeostasisGlycogen phosphorylase, liver formHomo sapiens (human)
necroptotic processGlycogen phosphorylase, liver formHomo sapiens (human)
glycogen catabolic processGlycogen phosphorylase, liver formHomo sapiens (human)
glycogen biosynthetic processGlycogen debranching enzymeHomo sapiens (human)
glycogen catabolic processGlycogen debranching enzymeHomo sapiens (human)
response to nutrientGlycogen debranching enzymeHomo sapiens (human)
response to glucocorticoidGlycogen debranching enzymeHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
carbohydrate metabolic processNon-lysosomal glucosylceramidaseHomo sapiens (human)
glucosylceramide catabolic processNon-lysosomal glucosylceramidaseHomo sapiens (human)
cholesterol metabolic processNon-lysosomal glucosylceramidaseHomo sapiens (human)
bile acid metabolic processNon-lysosomal glucosylceramidaseHomo sapiens (human)
glycoside catabolic processNon-lysosomal glucosylceramidaseHomo sapiens (human)
central nervous system neuron developmentNon-lysosomal glucosylceramidaseHomo sapiens (human)
lipid glycosylationNon-lysosomal glucosylceramidaseHomo sapiens (human)
regulation of actin filament polymerizationNon-lysosomal glucosylceramidaseHomo sapiens (human)
regulation of microtubule polymerizationNon-lysosomal glucosylceramidaseHomo sapiens (human)
glycosphingolipid catabolic processNon-lysosomal glucosylceramidaseHomo sapiens (human)
regulation of membrane lipid distributionNon-lysosomal glucosylceramidaseHomo sapiens (human)
central nervous system developmentNon-lysosomal glucosylceramidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (38)

Processvia Protein(s)Taxonomy
catalytic activityMaltase-glucoamylase, intestinalHomo sapiens (human)
glucan 1,4-alpha-glucosidase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
alpha-1,4-glucosidase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
protein bindingMaltase-glucoamylase, intestinalHomo sapiens (human)
amylase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
carbohydrate bindingMaltase-glucoamylase, intestinalHomo sapiens (human)
maltose alpha-glucosidase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
purine nucleobase bindingGlycogen phosphorylase, liver formHomo sapiens (human)
protein bindingGlycogen phosphorylase, liver formHomo sapiens (human)
ATP bindingGlycogen phosphorylase, liver formHomo sapiens (human)
glucose bindingGlycogen phosphorylase, liver formHomo sapiens (human)
glycogen phosphorylase activityGlycogen phosphorylase, liver formHomo sapiens (human)
AMP bindingGlycogen phosphorylase, liver formHomo sapiens (human)
vitamin bindingGlycogen phosphorylase, liver formHomo sapiens (human)
bile acid bindingGlycogen phosphorylase, liver formHomo sapiens (human)
identical protein bindingGlycogen phosphorylase, liver formHomo sapiens (human)
linear malto-oligosaccharide phosphorylase activityGlycogen phosphorylase, liver formHomo sapiens (human)
SHG alpha-glucan phosphorylase activityGlycogen phosphorylase, liver formHomo sapiens (human)
pyridoxal phosphate bindingGlycogen phosphorylase, liver formHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C delta typeRattus norvegicus (Norway rat)
glycogen debranching enzyme activityGlycogen debranching enzymeHomo sapiens (human)
4-alpha-glucanotransferase activityGlycogen debranching enzymeHomo sapiens (human)
amylo-alpha-1,6-glucosidase activityGlycogen debranching enzymeHomo sapiens (human)
protein bindingGlycogen debranching enzymeHomo sapiens (human)
polysaccharide bindingGlycogen debranching enzymeHomo sapiens (human)
polyubiquitin modification-dependent protein bindingGlycogen debranching enzymeHomo sapiens (human)
beta-maltose 4-alpha-glucanotransferase activityGlycogen debranching enzymeHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
galactosylceramidase activityNon-lysosomal glucosylceramidaseHomo sapiens (human)
glucosylceramidase activityNon-lysosomal glucosylceramidaseHomo sapiens (human)
beta-glucosidase activityNon-lysosomal glucosylceramidaseHomo sapiens (human)
glucosyltransferase activityNon-lysosomal glucosylceramidaseHomo sapiens (human)
steryl-beta-glucosidase activityNon-lysosomal glucosylceramidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (26)

Processvia Protein(s)Taxonomy
plasma membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
apical plasma membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
extracellular exosomeMaltase-glucoamylase, intestinalHomo sapiens (human)
tertiary granule membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
ficolin-1-rich granule membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
extracellular regionGlycogen phosphorylase, liver formHomo sapiens (human)
cytosolGlycogen phosphorylase, liver formHomo sapiens (human)
secretory granule lumenGlycogen phosphorylase, liver formHomo sapiens (human)
extracellular exosomeGlycogen phosphorylase, liver formHomo sapiens (human)
ficolin-1-rich granule lumenGlycogen phosphorylase, liver formHomo sapiens (human)
cytoplasmGlycogen phosphorylase, liver formHomo sapiens (human)
cytosolProtein kinase C delta typeRattus norvegicus (Norway rat)
cytosolProtein kinase C zeta typeRattus norvegicus (Norway rat)
extracellular regionGlycogen debranching enzymeHomo sapiens (human)
nucleusGlycogen debranching enzymeHomo sapiens (human)
cytoplasmGlycogen debranching enzymeHomo sapiens (human)
cytosolGlycogen debranching enzymeHomo sapiens (human)
inclusion bodyGlycogen debranching enzymeHomo sapiens (human)
sarcoplasmic reticulumGlycogen debranching enzymeHomo sapiens (human)
secretory granule lumenGlycogen debranching enzymeHomo sapiens (human)
ficolin-1-rich granule lumenGlycogen debranching enzymeHomo sapiens (human)
isoamylase complexGlycogen debranching enzymeHomo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
Golgi membraneNon-lysosomal glucosylceramidaseHomo sapiens (human)
endoplasmic reticulum membraneNon-lysosomal glucosylceramidaseHomo sapiens (human)
smooth endoplasmic reticulumNon-lysosomal glucosylceramidaseHomo sapiens (human)
cytosolNon-lysosomal glucosylceramidaseHomo sapiens (human)
plasma membraneNon-lysosomal glucosylceramidaseHomo sapiens (human)
membraneNon-lysosomal glucosylceramidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (197)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1214500Cmax in cynomolgus monkey treated with 3 mg/kg, po CS-1036 administered as single dose by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1688687Inhibition of Saccharomyces cerevisiae alpha-glucosidase using PNPG as substrate incubated for 10 mins by spectrophotometric method2020European journal of medicinal chemistry, Feb-15, Volume: 188Discovery of novel pyrido-pyrrolidine hybrid compounds as alpha-glucosidase inhibitors and alternative agent for control of type 1 diabetes.
AID324681Inhibition of human lysosomal alpha glucosidase2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Effect of five-membered sugar mimics on mammalian glycogen-degrading enzymes and various glucosidases.
AID1879713Inhibition of bovine liver beta-galactosidase assessed as release of p-nitrophenol at 1000 uM using p-nitrophenyl glycoside as substrate by spectrometric assay relative to control2022European journal of medicinal chemistry, Apr-05, Volume: 233Design, synthesis and glycosidase inhibition of C-4 branched LAB and DAB derivatives.
AID1214406Tmax in F344 rat treated with 1 mg/kg, po CS-1036 administered as single dose by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1884464Inhibition of almond beta-glucosidase assessed as reduction of p-nitrophenol release using p-nitrophenyl-glycoside as substrate by spectrophotometric analysis2022European journal of medicinal chemistry, Aug-05, Volume: 238trans, trans-2-C-Aryl-3,4-dihydroxypyrrolidines as potent and selective β-glucosidase inhibitors: Pharmacological chaperones for Gaucher disease.
AID1214511Drug level in F344 rat treated with 3 mg/kg, iv CS-1036 administered as single dose assessed as ratio of molar based AUClast by LC-MS/MS method relative to CS-10362013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1214512Drug level in F344 rat treated with 10 mg/kg, iv CS-1036 administered as single dose assessed as ratio of molar based AUClast by LC-MS/MS method relative to CS-10362013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID338552Inhibition of rat epididymis alpha-mannosidase assessed as p-nitrophenol release by spectrophotometrically2002Journal of natural products, Feb, Volume: 65, Issue:2
New sugar-mimic alkaloids from the pods of Angylocalyx pynaertii.
AID338568Inhibition of yeast isomaltase alpha-glucosidase assessed as p-nitrophenol release by spectrophotometrically2002Journal of natural products, Feb, Volume: 65, Issue:2
New sugar-mimic alkaloids from the pods of Angylocalyx pynaertii.
AID1884476Inhibition of bovine kidney alpha-L-fucosidase assessed as reduction of p-nitrophenol release using p-nitrophenyl-glycoside as substrate at 1000 uM by spectrophotometric analysis2022European journal of medicinal chemistry, Aug-05, Volume: 238trans, trans-2-C-Aryl-3,4-dihydroxypyrrolidines as potent and selective β-glucosidase inhibitors: Pharmacological chaperones for Gaucher disease.
AID338559Inhibition of bovine liver beta-galactosidase assessed as p-nitrophenol release at 1000 uM by spectrophotometrically2002Journal of natural products, Feb, Volume: 65, Issue:2
New sugar-mimic alkaloids from the pods of Angylocalyx pynaertii.
AID1688675Inhibition of Wistar rat intestinal maltase assessed as reduction in released D-glucose level using maltose as substrate by colorimetric assay2020European journal of medicinal chemistry, Feb-15, Volume: 188Discovery of novel pyrido-pyrrolidine hybrid compounds as alpha-glucosidase inhibitors and alternative agent for control of type 1 diabetes.
AID324677Inhibition of yeast alpha-glucosidase2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Effect of five-membered sugar mimics on mammalian glycogen-degrading enzymes and various glucosidases.
AID99232Inhibition of Glycosidases (lactase)in rat intestinal brush border membranes by D-glucose oxidase-peroxidase method1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.
AID1214567Oral bioavailability in rat at 10 mg/kg2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1214557Drug distribution in cecum of F344 rat treated with [14C]CS-1036 at 1 mg/kg, po administered as single dose after 8 hrs by scintillation counting method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1212379Drug excretion in po dosed rat urine dosed as [14C]CS-1036 assessed as 1,4-dideoxy-1,4-imino-D-arabinitol (M1) level up to 24 hrs2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Tissue distribution and identification of radioactivity components at elimination phase after oral administration of [¹⁴C]CS-1036, an α-amylase inhibitor, to rats.
AID1884467Inhibition of bovine liver beta-glucosidase assessed as reduction of p-nitrophenol release using p-nitrophenyl-glycoside as substrate at 1000 uM by spectrophotometric analysis2022European journal of medicinal chemistry, Aug-05, Volume: 238trans, trans-2-C-Aryl-3,4-dihydroxypyrrolidines as potent and selective β-glucosidase inhibitors: Pharmacological chaperones for Gaucher disease.
AID1214402Drug level in urine of po dosed monkey treated with [14C]CS-1036 by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1214416Cmax in F344 rat treated with 3 mg/kg, po CS-1036 administered as single dose by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID36808Inhibition of endoplasmic reticulum Alpha-Glucosidase II in rat liver1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.
AID324680Inhibition of rat sucrase2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Effect of five-membered sugar mimics on mammalian glycogen-degrading enzymes and various glucosidases.
AID1214377Drug level in urine of F344 rat treated with [14C]CS-1036 by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1879722Inhibition of Penicillium decumbens alpha-L-rhamnosidase assessed as release of p-nitrophenol at 1000 uM using p-nitrophenyl glycoside as substrate by spectrometric assay relative to control2022European journal of medicinal chemistry, Apr-05, Volume: 233Design, synthesis and glycosidase inhibition of C-4 branched LAB and DAB derivatives.
AID1884485Inhibition of bovine liver beta-glucuronidase assessed as reduction of p-nitrophenol release using p-nitrophenyl-glycoside as substrate at 1000 uM by spectrophotometric analysis2022European journal of medicinal chemistry, Aug-05, Volume: 238trans, trans-2-C-Aryl-3,4-dihydroxypyrrolidines as potent and selective β-glucosidase inhibitors: Pharmacological chaperones for Gaucher disease.
AID1214510AUClast in cynomolgus monkey treated with 10 mg/kg, po CS-1036 administered as single dose by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1322881Inhibition of Helix pomatia beta-mannosidase at 2 mM after 10 to 30 mins by spectrophotometric method2016European journal of medicinal chemistry, Oct-04, Volume: 121Inhibitor versus chaperone behaviour of d-fagomine, DAB and LAB sp(2)-iminosugar conjugates against glycosidases: A structure-activity relationship study in Gaucher fibroblasts.
AID1879704Inhibition of yeast alpha-glucosidase assessed as release of p-nitrophenol using p-nitrophenyl glycoside as substrate by spectrometric assay2022European journal of medicinal chemistry, Apr-05, Volume: 233Design, synthesis and glycosidase inhibition of C-4 branched LAB and DAB derivatives.
AID342974Inhibition of basal glycogenolysis in rat primary hepatocytes2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
AID1214409Tmax in cynomolgus monkey treated with 1 mg/kg, po CS-1036 administered as single dose by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1214564Inhibition of glycogen phosphorylase in rat hepatocytes assessed as reduction in basal glycogenolysis2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1214403Tmax in F344 rat treated with 3 mg/kg, iv CS-1036 administered as single dose by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID105269Concentration giving 50% inhibition of HIV-1 induced cytopathogenicity in MOLT-4 cells1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.
AID1214401Drug level in urine of po dosed F344 rat treated with [14C]CS-1036 by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1879702Inhibition of bovine liver beta-glucosidase assessed as release of p-nitrophenol using p-nitrophenyl glycoside as substrate by spectrometric assay2022European journal of medicinal chemistry, Apr-05, Volume: 233Design, synthesis and glycosidase inhibition of C-4 branched LAB and DAB derivatives.
AID36809Inhibition of lysosomal Alpha-Glucosidase II in rat liver1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.
AID1214508AUClast in cynomolgus monkey treated with 1 mg/kg, po CS-1036 administered as single dose by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1214507AUClast in F344 rat treated with 10 mg/kg, po CS-1036 administered as single dose by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1879720Inhibition of porcine kidney alpha-trehalase assessed as release of p-nitrophenol using p-nitrophenyl glycoside as substrate by spectrometric assay2022European journal of medicinal chemistry, Apr-05, Volume: 233Design, synthesis and glycosidase inhibition of C-4 branched LAB and DAB derivatives.
AID1688674Inhibition of Saccharomyces cerevisiae alpha-glucosidase assessed as reduction in p-nitrophenol release using p-nitrophenyl glycoside as substrate by spectrophotometric analysis2020European journal of medicinal chemistry, Feb-15, Volume: 188Discovery of novel pyrido-pyrrolidine hybrid compounds as alpha-glucosidase inhibitors and alternative agent for control of type 1 diabetes.
AID101850Inhibitory activity against pig Liver glycogen phosphorylase a2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Identification, synthesis, and characterization of new glycogen phosphorylase inhibitors binding to the allosteric AMP site.
AID1884473Inhibition of jack bean alpha-mannosidase assessed as reduction of p-nitrophenol release using p-nitrophenyl-glycoside as substrate by spectrophotometric analysis2022European journal of medicinal chemistry, Aug-05, Volume: 238trans, trans-2-C-Aryl-3,4-dihydroxypyrrolidines as potent and selective β-glucosidase inhibitors: Pharmacological chaperones for Gaucher disease.
AID1884475Inhibition of snail beta-mannosidase assessed as reduction of p-nitrophenol release using p-nitrophenyl-glycoside as substrate at 1000 uM by spectrophotometric analysis2022European journal of medicinal chemistry, Aug-05, Volume: 238trans, trans-2-C-Aryl-3,4-dihydroxypyrrolidines as potent and selective β-glucosidase inhibitors: Pharmacological chaperones for Gaucher disease.
AID1214545Drug excretion in urine of F344 rat treated with [14C]CS-1036 at 1 mg/kg, po administered as single dose after 24 hrs by scintillation counting method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1322867Competitive inhibition of baker's yeast alpha-glucosidase using alpha-D-glycopyranoside as substrate after 10 to 30 mins by Lineweaver-Burk plot analysis2016European journal of medicinal chemistry, Oct-04, Volume: 121Inhibitor versus chaperone behaviour of d-fagomine, DAB and LAB sp(2)-iminosugar conjugates against glycosidases: A structure-activity relationship study in Gaucher fibroblasts.
AID1214568Cmax in rat at 10 mg/kg, po2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1214378Drug level in feces of F344 rat treated with [14C]CS-1036 by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID324673Inhibition of amylo-1,6-glucosidase2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Effect of five-membered sugar mimics on mammalian glycogen-degrading enzymes and various glucosidases.
AID108106Inhibitory activity against Mannosidase in jack bean (Canavalia ensiformis)1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Design of potential anti-HIV agents. 1. Mannosidase inhibitors.
AID338548Inhibition of rat intestinal sucrase assessed as glucose release by Glucose B-test2002Journal of natural products, Feb, Volume: 65, Issue:2
New sugar-mimic alkaloids from the pods of Angylocalyx pynaertii.
AID1214404Tmax in F344 rat treated with 10 mg/kg, iv CS-1036 administered as single dose by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1214408Tmax in F344 rat treated with 10 mg/kg, po CS-1036 administered as single dose by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1214504AUClast in F344 rat treated with 0.3 mg/kg, po CS-1036 administered as single dose by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1214411Tmax in cynomolgus monkey treated with 10 mg/kg, po CS-1036 administered as single dose by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1884472Inhibition of bovine liver beta-galactosidase assessed as reduction of p-nitrophenol release using p-nitrophenyl-glycoside as substrate at 1000 uM by spectrophotometric analysis2022European journal of medicinal chemistry, Aug-05, Volume: 238trans, trans-2-C-Aryl-3,4-dihydroxypyrrolidines as potent and selective β-glucosidase inhibitors: Pharmacological chaperones for Gaucher disease.
AID1214509AUClast in cynomolgus monkey treated with 3 mg/kg, po CS-1036 administered as single dose by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1212374Half life in po dosed rat dosed and assessed as 1,4-dideoxy-1,4-imino-D-arabinitol level (M1)2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Tissue distribution and identification of radioactivity components at elimination phase after oral administration of [¹⁴C]CS-1036, an α-amylase inhibitor, to rats.
AID324676Inhibition of rice alpha-glucosidase2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Effect of five-membered sugar mimics on mammalian glycogen-degrading enzymes and various glucosidases.
AID1214410Tmax in cynomolgus monkey treated with 3 mg/kg, po CS-1036 administered as single dose by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID296106Inhibition of jack bean alpha-D-mannosidase2007Bioorganic & medicinal chemistry, Jun-15, Volume: 15, Issue:12
Synthesis and evaluation of amino-threoses in D- and L-series: are five membered ring amino-sugars more potent glycosidase inhibitors than the six membered ones?
AID1212376Drug metabolism in po dosed rat in intestinal flora treated with [14C]CS-1036 by liquid scintillation counting2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Tissue distribution and identification of radioactivity components at elimination phase after oral administration of [¹⁴C]CS-1036, an α-amylase inhibitor, to rats.
AID1214415Cmax in F344 rat treated with 1 mg/kg, po CS-1036 administered as single dose by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1322877Inhibition of Penicillium decumbens naringinase at 2 mM after 10 to 30 mins by spectrophotometric method2016European journal of medicinal chemistry, Oct-04, Volume: 121Inhibitor versus chaperone behaviour of d-fagomine, DAB and LAB sp(2)-iminosugar conjugates against glycosidases: A structure-activity relationship study in Gaucher fibroblasts.
AID1214542Drug level in cynomolgus monkey treated with 10 mg/kg, po CS-1036 administered as single dose assessed as ratio of molar based AUClast by LC-MS/MS method relative to CS-10362013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1322880Inhibition of jack bean alpha-mannosidase at 2 mM after 10 to 30 mins by spectrophotometric method2016European journal of medicinal chemistry, Oct-04, Volume: 121Inhibitor versus chaperone behaviour of d-fagomine, DAB and LAB sp(2)-iminosugar conjugates against glycosidases: A structure-activity relationship study in Gaucher fibroblasts.
AID1214414Cmax in F344 rat treated with 0.3 mg/kg, po CS-1036 administered as single dose by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1212360Drug metabolism in albino F344/DuCrlCrlj rat plasma protein treated with at 10 mg/kg, po of [14C]CS-1036 administered for 5 days by liquid scintillation counting2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Tissue distribution and identification of radioactivity components at elimination phase after oral administration of [¹⁴C]CS-1036, an α-amylase inhibitor, to rats.
AID1214565Inhibition of glycogen phosphorylase in rat hepatocytes assessed as reduction in glucagom-induced glycogenolysis2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID35262Inhibition of golgi Alpha-mannosidase II in rat liver1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.
AID105266Concentration giving 50% inhibition of growth of mock-infected MOLT-4 cells1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.
AID1879695Inhibition of almond beta-glucosidase assessed as release of p-nitrophenol using p-nitrophenyl glycoside as substrate by spectrometric assay2022European journal of medicinal chemistry, Apr-05, Volume: 233Design, synthesis and glycosidase inhibition of C-4 branched LAB and DAB derivatives.
AID338557Inhibition of coffee bean alpha-galactosidase assessed as p-nitrophenol release at 1000 uM by spectrophotometrically2002Journal of natural products, Feb, Volume: 65, Issue:2
New sugar-mimic alkaloids from the pods of Angylocalyx pynaertii.
AID1884477Inhibition of porcine kidney alpha-trehalase assessed as reduction of p-nitrophenol release using p-nitrophenyl-glycoside as substrate by spectrophotometric analysis2022European journal of medicinal chemistry, Aug-05, Volume: 238trans, trans-2-C-Aryl-3,4-dihydroxypyrrolidines as potent and selective β-glucosidase inhibitors: Pharmacological chaperones for Gaucher disease.
AID1322878Inhibition of green coffee bean alpha-galactosidase using o-nitrophenyl alpha-D-galactopyranoside at 2 mM after 10 to 30 mins by spectrophotometric method2016European journal of medicinal chemistry, Oct-04, Volume: 121Inhibitor versus chaperone behaviour of d-fagomine, DAB and LAB sp(2)-iminosugar conjugates against glycosidases: A structure-activity relationship study in Gaucher fibroblasts.
AID1884468Inhibition of human lysosomal beta-glucosidase assessed as reduction of p-nitrophenol release using p-nitrophenyl-glycoside as substrate by spectrophotometric analysis2022European journal of medicinal chemistry, Aug-05, Volume: 238trans, trans-2-C-Aryl-3,4-dihydroxypyrrolidines as potent and selective β-glucosidase inhibitors: Pharmacological chaperones for Gaucher disease.
AID324671Inhibition of rabbit muscle glycogen phosphorylase b2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Effect of five-membered sugar mimics on mammalian glycogen-degrading enzymes and various glucosidases.
AID1276735Inhibition of rabbit muscle glycogen phosphorylase using tritium-labeled glycogen as substrate by scintillation counter2016European journal of medicinal chemistry, Jan-27, Volume: 108Glucose-derived spiro-isoxazolines are anti-hyperglycemic agents against type 2 diabetes through glycogen phosphorylase inhibition.
AID1214394Drug level in anaerobic culture broth of monkey feces derived anaerobic culture broth treated with [14C]CS-1036 at 63.5 uCi/ml after 24 hrs at 35 degC by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID338554Inhibition of rat epididymis beta-mannosidase assessed as p-nitrophenol release by spectrophotometrically2002Journal of natural products, Feb, Volume: 65, Issue:2
New sugar-mimic alkaloids from the pods of Angylocalyx pynaertii.
AID1214539Drug level in F344 rat treated with 10 mg/kg, po CS-1036 administered as single dose assessed as ratio of molar based AUClast by LC-MS/MS method relative to CS-10362013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1212356Drug level in albino F344/DuCrlCrlj rat plasma treated with [14C]CS-1036 at 10 mg/kg, po after 8 to 72 hrs by liquid scintillation counting2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Tissue distribution and identification of radioactivity components at elimination phase after oral administration of [¹⁴C]CS-1036, an α-amylase inhibitor, to rats.
AID324678Inhibition of rat intestinal maltase2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Effect of five-membered sugar mimics on mammalian glycogen-degrading enzymes and various glucosidases.
AID324685Inhibition of glucagon-stimulated glycogenolysis in Wistar rat hepatocytes assessed as glucose release after 90 mins2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Effect of five-membered sugar mimics on mammalian glycogen-degrading enzymes and various glucosidases.
AID1214536Drug level in F344 rat treated with 0.3 mg/kg, po CS-1036 administered as single dose assessed as ratio of molar based AUClast by LC-MS/MS method relative to CS-10362013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID342975Inhibition of amylo-1,6-glucosidase2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
AID324679Inhibition of rat isomaltase2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Effect of five-membered sugar mimics on mammalian glycogen-degrading enzymes and various glucosidases.
AID1214556Drug distribution in cecum of F344 rat treated with [14C]CS-1036 at 1 mg/kg, po administered as single dose by scintillation counting method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1214549Drug excretion in feces of cynomolgus monkey treated with [14C]CS-1036 at 1 mg/kg, po administered as single dose after 48 hrs by scintillation counting method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1879706Inhibition of rice alpha-glucosidase assessed as release of p-nitrophenol using p-nitrophenyl glycoside as substrate by spectrometric assay2022European journal of medicinal chemistry, Apr-05, Volume: 233Design, synthesis and glycosidase inhibition of C-4 branched LAB and DAB derivatives.
AID1214418Cmax in cynomolgus monkey treated with 1 mg/kg, po CS-1036 administered as single dose by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID324686Inhibition of human lysosomal beta glucosidase2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Effect of five-membered sugar mimics on mammalian glycogen-degrading enzymes and various glucosidases.
AID1879718Inhibition of bovine kidney alpha-L-fucosidase assessed as release of p-nitrophenol using p-nitrophenyl glycoside as substrate by spectrometric assay2022European journal of medicinal chemistry, Apr-05, Volume: 233Design, synthesis and glycosidase inhibition of C-4 branched LAB and DAB derivatives.
AID1214538Drug level in F344 rat treated with 3 mg/kg, po CS-1036 administered as single dose assessed as ratio of molar based AUClast by LC-MS/MS method relative to CS-10362013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1879714Inhibition of jack bean alpha-mannosidase assessed as release of p-nitrophenol using p-nitrophenyl glycoside as substrate by spectrometric assay2022European journal of medicinal chemistry, Apr-05, Volume: 233Design, synthesis and glycosidase inhibition of C-4 branched LAB and DAB derivatives.
AID1322879Inhibition of Escherichia coli beta-galactosidase using o-nitrophenyl beta-D-galactopyranoside at 2 mM after 10 to 30 mins by spectrophotometric method2016European journal of medicinal chemistry, Oct-04, Volume: 121Inhibitor versus chaperone behaviour of d-fagomine, DAB and LAB sp(2)-iminosugar conjugates against glycosidases: A structure-activity relationship study in Gaucher fibroblasts.
AID1884454Inhibition of yeast alpha-glucosidase assessed as reduction of p-nitrophenol release using p-nitrophenyl-glycoside as substrate by spectrophotometric analysis2022European journal of medicinal chemistry, Aug-05, Volume: 238trans, trans-2-C-Aryl-3,4-dihydroxypyrrolidines as potent and selective β-glucosidase inhibitors: Pharmacological chaperones for Gaucher disease.
AID1884484Inhibition of Escherichia coli beta-glucuronidase assessed as reduction of p-nitrophenol release using p-nitrophenyl-glycoside as substrate at 1000 uM by spectrophotometric analysis2022European journal of medicinal chemistry, Aug-05, Volume: 238trans, trans-2-C-Aryl-3,4-dihydroxypyrrolidines as potent and selective β-glucosidase inhibitors: Pharmacological chaperones for Gaucher disease.
AID1884482Inhibition of Penicillium decumbens alpha-L-rhamnosidase assessed as reduction of p-nitrophenol release using p-nitrophenyl-glycoside as substrate at 1000 uM by spectrophotometric analysis2022European journal of medicinal chemistry, Aug-05, Volume: 238trans, trans-2-C-Aryl-3,4-dihydroxypyrrolidines as potent and selective β-glucosidase inhibitors: Pharmacological chaperones for Gaucher disease.
AID1879698Inhibition of rat intestinal maltase assessed as release of D-glucose using maltose as substrate by colorimetric analysis2022European journal of medicinal chemistry, Apr-05, Volume: 233Design, synthesis and glycosidase inhibition of C-4 branched LAB and DAB derivatives.
AID35368Competitive Inhibitory activity against Golgi Alpha-mannosidase II1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.
AID338545Inhibition of yeast alpha-glucosidase assessed as p-nitrophenol release by spectrophotometrically2002Journal of natural products, Feb, Volume: 65, Issue:2
New sugar-mimic alkaloids from the pods of Angylocalyx pynaertii.
AID1214540Drug level in cynomolgus monkey treated with 1 mg/kg, po CS-1036 administered as single dose assessed as ratio of molar based AUClast by LC-MS/MS method relative to CS-10362013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1884479Inhibition of Aspergillus niger amyloglucosidase assessed as reduction of p-nitrophenol release using p-nitrophenyl-glycoside as substrate by spectrophotometric analysis2022European journal of medicinal chemistry, Aug-05, Volume: 238trans, trans-2-C-Aryl-3,4-dihydroxypyrrolidines as potent and selective β-glucosidase inhibitors: Pharmacological chaperones for Gaucher disease.
AID35369Inhibition of lysosomal Alpha-mannosidase II in rat liver1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.
AID1819251Inhibition of Maltase (unknown origin)2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
5-
AID338550Inhibition of rat intestinal isomaltase assessed as glucose release by Glucose B-test2002Journal of natural products, Feb, Volume: 65, Issue:2
New sugar-mimic alkaloids from the pods of Angylocalyx pynaertii.
AID1884456Inhibition of rice alpha-glucosidase assessed as reduction of p-nitrophenol release using p-nitrophenyl-glycoside as substrate by spectrophotometric analysis2022European journal of medicinal chemistry, Aug-05, Volume: 238trans, trans-2-C-Aryl-3,4-dihydroxypyrrolidines as potent and selective β-glucosidase inhibitors: Pharmacological chaperones for Gaucher disease.
AID1884458Inhibition of rat small intestinal maltase assessed as reduction of D-glucose release using maltose as substrate by colorimetric analysis2022European journal of medicinal chemistry, Aug-05, Volume: 238trans, trans-2-C-Aryl-3,4-dihydroxypyrrolidines as potent and selective β-glucosidase inhibitors: Pharmacological chaperones for Gaucher disease.
AID210969Inhibition of Glycosidases (trehalase)in rat intestinal brush border membranes by D-glucose oxidase-peroxidase method1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.
AID52058Inhibition of Cellobiase in rat intestinal brush border membranes by D-glucose oxidase-peroxidase method1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.
AID1322870Competitive inhibition of bovine liver cytosolic beta-glucosidase using beta-D-glycopyranoside as substrate after 10 to 30 mins by Lineweaver-Burk plot analysis2016European journal of medicinal chemistry, Oct-04, Volume: 121Inhibitor versus chaperone behaviour of d-fagomine, DAB and LAB sp(2)-iminosugar conjugates against glycosidases: A structure-activity relationship study in Gaucher fibroblasts.
AID1884470Inhibition of coffee beans alpha-galactosidase assessed as reduction of p-nitrophenol release using p-nitrophenyl-glycoside as substrate at 1000 uM by spectrophotometric analysis2022European journal of medicinal chemistry, Aug-05, Volume: 238trans, trans-2-C-Aryl-3,4-dihydroxypyrrolidines as potent and selective β-glucosidase inhibitors: Pharmacological chaperones for Gaucher disease.
AID338543Inhibition of rice alpha-glucosidase assessed as glucose release by Glucose B-test2002Journal of natural products, Feb, Volume: 65, Issue:2
New sugar-mimic alkaloids from the pods of Angylocalyx pynaertii.
AID36810Competitive Inhibitory activity against Endoplasmic reticulum Alpha-Glucosidase II1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.
AID1322868Competitive inhibition of baker's yeast isomaltase after 10 to 30 mins by Lineweaver-Burk plot analysis2016European journal of medicinal chemistry, Oct-04, Volume: 121Inhibitor versus chaperone behaviour of d-fagomine, DAB and LAB sp(2)-iminosugar conjugates against glycosidases: A structure-activity relationship study in Gaucher fibroblasts.
AID105142Concentration giving 50% inhibition of HIV-1 induced cytopathogenicity in MT-4 cells1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.
AID338561Inhibition of bovine epididymis alpha-L-fucosidase assessed as p-nitrophenol release at 1000 uM by spectrophotometrically2002Journal of natural products, Feb, Volume: 65, Issue:2
New sugar-mimic alkaloids from the pods of Angylocalyx pynaertii.
AID342807Inhibition of glucagon-induced glucose production in rat primary hepatocytes2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
AID1214501Cmax in cynomolgus monkey treated with 10 mg/kg, po CS-1036 administered as single dose by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1212378Oral bioavailability in rat dosed and assessed as 1,4-dideoxy-1,4-imino-D-arabinitol level (M1)2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Tissue distribution and identification of radioactivity components at elimination phase after oral administration of [¹⁴C]CS-1036, an α-amylase inhibitor, to rats.
AID338562Inhibition of Aspergillus niger amyloglucosidase assessed as glucose release by Glucose B-test2002Journal of natural products, Feb, Volume: 65, Issue:2
New sugar-mimic alkaloids from the pods of Angylocalyx pynaertii.
AID104667Inhibition of Glycosidases (maltase) in rat intestinal brush border membranes by D-glucose oxidase-peroxidase method1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.
AID1214393Drug level in anaerobic culture broth of F344 rat cecal content treated with [14C]CS-1036 at 63.5 uCi/ml after 24 hrs at 35 degC by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1214405Tmax in F344 rat treated with 0.3 mg/kg, po CS-1036 administered as single dose by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1879700Inhibition of rat intestinal sucrase assessed as release of p-nitrophenol using p-nitrophenyl glycoside as substrate by spectrometric assay2022European journal of medicinal chemistry, Apr-05, Volume: 233Design, synthesis and glycosidase inhibition of C-4 branched LAB and DAB derivatives.
AID1214502AUClast in F344 rat treated with 3 mg/kg, iv CS-1036 administered as single dose by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1688692Inhibition of jack bean alpha-mannosidase at 1 mM using PNPG as substrate incubated for 10 mins by spectrophotometric method2020European journal of medicinal chemistry, Feb-15, Volume: 188Discovery of novel pyrido-pyrrolidine hybrid compounds as alpha-glucosidase inhibitors and alternative agent for control of type 1 diabetes.
AID338567Inhibition of yeast maltase alpha-glucosidase assessed as p-nitrophenol release by spectrophotometrically2002Journal of natural products, Feb, Volume: 65, Issue:2
New sugar-mimic alkaloids from the pods of Angylocalyx pynaertii.
AID1322869Competitive inhibition of Aspergillus niger amyloglucosidase after 10 to 30 mins by Lineweaver-Burk plot analysis2016European journal of medicinal chemistry, Oct-04, Volume: 121Inhibitor versus chaperone behaviour of d-fagomine, DAB and LAB sp(2)-iminosugar conjugates against glycosidases: A structure-activity relationship study in Gaucher fibroblasts.
AID1214548Drug excretion in urine of cynomolgus monkey treated with [14C]CS-1036 at 1 mg/kg, po administered as single dose after 48 hrs by scintillation counting method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1884460Inhibition of rat small intestinal sucrase assessed as reduction of p-nitrophenol release using p-nitrophenyl-glycoside as substrate by spectrophotometric analysis2022European journal of medicinal chemistry, Aug-05, Volume: 238trans, trans-2-C-Aryl-3,4-dihydroxypyrrolidines as potent and selective β-glucosidase inhibitors: Pharmacological chaperones for Gaucher disease.
AID296105Inhibition of almond beta-D-glucosidase2007Bioorganic & medicinal chemistry, Jun-15, Volume: 15, Issue:12
Synthesis and evaluation of amino-threoses in D- and L-series: are five membered ring amino-sugars more potent glycosidase inhibitors than the six membered ones?
AID1214554Drug distribution in stomach of F344 rat treated with [14C]CS-1036 at 1 mg/kg, po administered as single dose after 2 to 8 hrs by scintillation counting method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1214503AUClast in F344 rat treated with 10 mg/kg, iv CS-1036 administered as single dose by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID208985Inhibition of Sucrase in rat intestinal brush border membranes by D-glucose oxidase-peroxidase method1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.
AID1214412Cmax in F344 rat treated with 3 mg/kg, iv CS-1036 administered as single dose by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1214555Drug distribution in intestine of F344 rat treated with [14C]CS-1036 at 1 mg/kg, po administered as single dose after 2 to 8 hrs by scintillation counting method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1214505AUClast in F344 rat treated with 1 mg/kg, po CS-1036 administered as single dose by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1879723Inhibition of Escherichia coli beta-glucuronidase assessed as release of p-nitrophenol using p-nitrophenyl glycoside as substrate by spectrometric assay2022European journal of medicinal chemistry, Apr-05, Volume: 233Design, synthesis and glycosidase inhibition of C-4 branched LAB and DAB derivatives.
AID1214506AUClast in F344 rat treated with 3 mg/kg, po CS-1036 administered as single dose by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID338569Inhibition of pig kidney trehalase assessed as p-nitrophenol release by spectrophotometrically2002Journal of natural products, Feb, Volume: 65, Issue:2
New sugar-mimic alkaloids from the pods of Angylocalyx pynaertii.
AID1214537Drug level in F344 rat treated with 1 mg/kg, po CS-1036 administered as single dose assessed as ratio of molar based AUClast by LC-MS/MS method relative to CS-10362013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1879716Inhibition of snail beta-mannosidase assessed as release of p-nitrophenol at 1000 uM using p-nitrophenyl glycoside as substrate by spectrometric assay relative control2022European journal of medicinal chemistry, Apr-05, Volume: 233Design, synthesis and glycosidase inhibition of C-4 branched LAB and DAB derivatives.
AID1879711Inhibition of coffee beans alpha-galactosidase assessed as release of p-nitrophenol at 1000 uM using p-nitrophenyl glycoside as substrate by spectrometric assay relative to control2022European journal of medicinal chemistry, Apr-05, Volume: 233Design, synthesis and glycosidase inhibition of C-4 branched LAB and DAB derivatives.
AID1214541Drug level in cynomolgus monkey treated with 3 mg/kg, po CS-1036 administered as single dose assessed as ratio of molar based AUClast by LC-MS/MS method relative to CS-10362013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID281458Inhibition of yeast alpha-glucosidase2007Journal of natural products, Mar, Volume: 70, Issue:3
Occurrence of the alpha-glucosidase inhibitor 1,4-Dideoxy-1,4-imino-D-arabinitol and related iminopentitols in marine sponges.
AID1214395Drug level in anaerobic culture broth of human feces derived anaerobic culture broth treated with [14C]CS-1036 at 63.5 uCi/ml after 24 hrs at 35 degC by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1322871Competitive inhibition of almond beta-glucosidase using beta-D-glycopyranoside as substrate after 10 to 30 mins by Lineweaver-Burk plot analysis2016European journal of medicinal chemistry, Oct-04, Volume: 121Inhibitor versus chaperone behaviour of d-fagomine, DAB and LAB sp(2)-iminosugar conjugates against glycosidases: A structure-activity relationship study in Gaucher fibroblasts.
AID104771Concentration giving 50% inhibition of growth of mock-infected MT-4 cells1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.
AID1884462Inhibition of human lysosomal alpha-glucosidase assessed as reduction of p-nitrophenol release using p-nitrophenyl-glycoside as substrate by spectrophotometric analysis2022European journal of medicinal chemistry, Aug-05, Volume: 238trans, trans-2-C-Aryl-3,4-dihydroxypyrrolidines as potent and selective β-glucosidase inhibitors: Pharmacological chaperones for Gaucher disease.
AID338542Inhibition of rat intestinal maltase assessed as glucose release by Glucose B-test2002Journal of natural products, Feb, Volume: 65, Issue:2
New sugar-mimic alkaloids from the pods of Angylocalyx pynaertii.
AID1879717Inhibition of Aspergillus niger amyloglucosidase assessed as release of p-nitrophenol using p-nitrophenyl glycoside as substrate by spectrometric assay2022European journal of medicinal chemistry, Apr-05, Volume: 233Design, synthesis and glycosidase inhibition of C-4 branched LAB and DAB derivatives.
AID1214566Inhibition of glycogen phosphorylase in ob/ob mouse2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1879701Inhibition of human lysosomal alpha glucosidase assessed as release of p-nitrophenol using p-nitrophenyl glycoside as substrate by spectrometric assay2022European journal of medicinal chemistry, Apr-05, Volume: 233Design, synthesis and glycosidase inhibition of C-4 branched LAB and DAB derivatives.
AID91639Inhibition of Glycosidases (isomaltase)in rat intestinal brush border membranes by D-glucose oxidase-peroxidase method1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.
AID1879725Inhibition of bovine liver beta-glucronidase assessed as release of p-nitrophenol using p-nitrophenyl glycoside as substrate by spectrometric assay2022European journal of medicinal chemistry, Apr-05, Volume: 233Design, synthesis and glycosidase inhibition of C-4 branched LAB and DAB derivatives.
AID1214413Cmax in F344 rat treated with 10 mg/kg, iv CS-1036 administered as single dose by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID1214417Cmax in F344 rat treated with 10 mg/kg, po CS-1036 administered as single dose by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID35370Inhibition of soluble Alpha-mannosidase II in rat liver1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.
AID1688690Inhibition of bovine kidney alpha-fucosidase at 1 mM using PNPG as substrate incubated for 10 mins by spectrophotometric method2020European journal of medicinal chemistry, Feb-15, Volume: 188Discovery of novel pyrido-pyrrolidine hybrid compounds as alpha-glucosidase inhibitors and alternative agent for control of type 1 diabetes.
AID296103Inhibition of yeast alpha-D-glucosidase2007Bioorganic & medicinal chemistry, Jun-15, Volume: 15, Issue:12
Synthesis and evaluation of amino-threoses in D- and L-series: are five membered ring amino-sugars more potent glycosidase inhibitors than the six membered ones?
AID335082Inhibition of yeast alpha-glucosidase1993Journal of natural products, Aug, Volume: 56, Issue:8
2-Hydroxymethyl-3,4-dihydroxy-6-methyl-pyrrolidine (6-deoxy-DMDP), an alkaloid beta-mannosidase inhibitor from seeds of Angylocalyx pynaertii.
AID1212377Clearance in po dosed rat dosed and assessed as 1,4-dideoxy-1,4-imino-D-arabinitol level (M1)2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Tissue distribution and identification of radioactivity components at elimination phase after oral administration of [¹⁴C]CS-1036, an α-amylase inhibitor, to rats.
AID1214407Tmax in F344 rat treated with 3 mg/kg, po CS-1036 administered as single dose by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID335083Inhibition of almonds beta-glucosidase1993Journal of natural products, Aug, Volume: 56, Issue:8
2-Hydroxymethyl-3,4-dihydroxy-6-methyl-pyrrolidine (6-deoxy-DMDP), an alkaloid beta-mannosidase inhibitor from seeds of Angylocalyx pynaertii.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (32)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (3.13)18.7374
1990's2 (6.25)18.2507
2000's9 (28.13)29.6817
2010's11 (34.38)24.3611
2020's9 (28.13)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.40 (24.57)
Research Supply Index3.50 (2.92)
Research Growth Index5.26 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other32 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]